HCID 57919205, compound → HCID 44463771, compound

Participants

Reaction Steps

Using the method described in Example 49, 2-[4-(2-chloro-phenoxy)-6-oxo-6H-pyridazin-1-yl]-3-(tetrahydro-pyran-4-yl)-propionic acid (Intermediate 101) and 1-(3-amino-pyrazol-1-yl)-2-methyl-propan-2-ol (Intermediate 1) afforded 2-[4-(2-chloro-phenoxy)-6-oxo-6H-pyridazin-1-yl]-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-3-(tetrahydro-pyran-4-yl)-propionamide as a white solid (560 mg); ES+-HRMS m/e calcd for C25H30N5O5Cl [M+H+] 516.2008 found 516.2008. 1H NMR (400 MHz, DMSO-d6) δ ppm 1.05 (s, 3H), 1.06 (s, 3H), 1.14-1.34 (m, 2H), 1.35-1.45 (m, 1H), 1.46-1.57 (m, 2H), 1.84-1.93 (m, 1H), 2.17-2.27 (m, 1H), 3.09-3.27 (m, 2H), 3.74-3.86 (m, 2H), 3.89 (s, 2H), 4.67 (s, 1H), 5.55 (dd, J=11.1, 4.0 Hz, 1H), 5.70 (d, J=2.8 Hz, 1H), 6.40 (d, J=2.1 Hz, 1H), 7.38-7.47 (m, 1H), 7.49-7.56 (m, 3H), 7.71 (d, J=7.9 Hz, 1H), 8.22 (d, J=2.8 Hz, 1H), 10.85 (s, 1H). Separation of enantiomers via supercritical fluid chromatography on a SFC DAICEL AD column, 45% methanol, 70 mL/min.

Provenance & Evidence